drugset / Trial / NCT03565458

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

NCT03565458

Phase 1 Unknown 48 enrolled LG Chem
RandomizedCrossoverOpen-labelTreatment

Summary

gemigliptin,SGLT-2i DDI study

Timeline

Start
2018-04-05
Primary completion
2018-08-20
Completion
2018-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject Empagliflozin Small molecule 25 mg Oral
Subject Gemigliptin Small molecule 50 mg Oral